Related Experiment Video
Updated: Jul 3, 2026
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
[Adalimumab: the molecule and manufacturing procedure].
Z Martínez de Lagrán1, S Pérez-Barrio, J L Díaz-Pérez
1Servicio de Dermatología. Hospital de Cruces. Cruces (Vizcaya). España. ZURINE.MARTINEZDELAGRANALVAREZDEARCAYA@osakidetza.net
Adalimumab is a biologic therapy targeting tumor necrosis factor alpha (TNF-alpha), a key driver of inflammatory diseases like psoriasis. Its complex production utilizes advanced phage display technology for targeted treatment.
Area of Science:
- Immunology
- Biotechnology
Context:
- Tumor necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine implicated in the pathogenesis of inflammatory diseases.
- Psoriasis is a chronic inflammatory condition where TNF-alpha plays a significant role.
Purpose:
- To describe Adalimumab, a fully human monoclonal antibody targeting TNF-alpha.
- To highlight the complex production process of Adalimumab using phage display technology.
Summary:
- Adalimumab is a monoclonal antibody designed to neutralize TNF-alpha.
- The manufacturing of Adalimumab involves sophisticated phage display techniques.
Impact:
- Adalimumab offers a targeted therapeutic approach for inflammatory conditions driven by TNF-alpha.
- Understanding its production is crucial for biologic drug development and manufacturing.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
11:09An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
Published on: April 17, 2018
